Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial

Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.

Saved in:
Bibliographic Details
Main Authors: Ley, Catherine autora, Mohar, Alejandro autor, Guarner, Jeannette autora, Herrera Goepfert, Roberto autor, Sánchez Figueroa, Luz autora, Halperin Frisch, David C. Doctor 1937-2000 autor 71, Jhohnstone, Iain autor/a, Parsonnet, Julie autor/a
Format: Texto biblioteca
Language:eng
Subjects:Neoplasias gástricas, Helicobacter pylori, Medicina preventiva, Artfrosur,
Online Access:https://doi.org/10.1158/1055-9965.EPI-03-0124
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-ECOSUR:26197
record_format koha
spelling KOHA-OAI-ECOSUR:261972024-03-11T15:26:17ZHelicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial Ley, Catherine autora Mohar, Alejandro autor Guarner, Jeannette autora Herrera Goepfert, Roberto autor Sánchez Figueroa, Luz autora Halperin Frisch, David C. Doctor 1937-2000 autor 71 Jhohnstone, Iain autor/a Parsonnet, Julie autor/a textengHelicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.Neoplasias gástricasHelicobacter pyloriMedicina preventivaArtfrosurCancer Epidemiology, Biomarkers and Preventionhttps://doi.org/10.1158/1055-9965.EPI-03-0124Disponible para usuarios de ECOSUR con su clave de acceso
institution ECOSUR
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-ecosur
tag biblioteca
region America del Norte
libraryname Sistema de Información Bibliotecario de ECOSUR (SIBE)
language eng
topic Neoplasias gástricas
Helicobacter pylori
Medicina preventiva
Artfrosur
Neoplasias gástricas
Helicobacter pylori
Medicina preventiva
Artfrosur
spellingShingle Neoplasias gástricas
Helicobacter pylori
Medicina preventiva
Artfrosur
Neoplasias gástricas
Helicobacter pylori
Medicina preventiva
Artfrosur
Ley, Catherine autora
Mohar, Alejandro autor
Guarner, Jeannette autora
Herrera Goepfert, Roberto autor
Sánchez Figueroa, Luz autora
Halperin Frisch, David C. Doctor 1937-2000 autor 71
Jhohnstone, Iain autor/a
Parsonnet, Julie autor/a
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
description Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.
format Texto
topic_facet Neoplasias gástricas
Helicobacter pylori
Medicina preventiva
Artfrosur
author Ley, Catherine autora
Mohar, Alejandro autor
Guarner, Jeannette autora
Herrera Goepfert, Roberto autor
Sánchez Figueroa, Luz autora
Halperin Frisch, David C. Doctor 1937-2000 autor 71
Jhohnstone, Iain autor/a
Parsonnet, Julie autor/a
author_facet Ley, Catherine autora
Mohar, Alejandro autor
Guarner, Jeannette autora
Herrera Goepfert, Roberto autor
Sánchez Figueroa, Luz autora
Halperin Frisch, David C. Doctor 1937-2000 autor 71
Jhohnstone, Iain autor/a
Parsonnet, Julie autor/a
author_sort Ley, Catherine autora
title Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
title_short Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
title_full Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
title_fullStr Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
title_full_unstemmed Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
title_sort helicobacter pylori eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
url https://doi.org/10.1158/1055-9965.EPI-03-0124
work_keys_str_mv AT leycatherineautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT moharalejandroautor helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT guarnerjeannetteautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT herreragoepfertrobertoautor helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT sanchezfigueroaluzautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT halperinfrischdavidcdoctor19372000autor71 helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT jhohnstoneiainautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
AT parsonnetjulieautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial
_version_ 1794790414155251712